



Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

April 22, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Executive Officer, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Status and Completion of Purchase of Own Shares

(Repurchase of Own Shares under the Provision of the Articles of Incorporation
Pursuant to Article 459, Paragraph 1 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the Company repurchased its own shares pursuant to Article 459, Paragraph 1 of the Companies Act of Japan and the provision of the Company’s Articles of Incorporation as detailed below.

This concludes Company's repurchase of its common stock authorized by the Board of Directors' meeting held on October 10, 2025.

- | | |
|--|---|
| 1. Class of shares repurchased: | Common stock |
| 2. Total number of shares repurchased: | 116,800 shares |
| 3. Total amount of shares repurchased: | 163,912,800 yen |
| 4. Repurchase period: | From April 1, 2026 to April 22, 2026 *1 |
| 5. Repurchase method: | Market purchase on the Tokyo Stock Exchange |

Reference:

1. Outline of the resolution at the Board of Directors’ meeting held on October 10, 2025 (announced on October 10, 2025)

- | | |
|---|---|
| (1) Class of shares to be repurchased: | Common stock |
| (2) Total number of shares to be repurchased: | Up to 1,000,000 shares
(Equivalent to 3.3% of the total number of issued shares (excluding treasury shares)) |
| (3) Total amount to be repurchased: | Up to 1,500 million yen |
| (4) Repurchase period: | From October 15, 2025 to May 22, 2026 *2 |

2. Cumulative number of own shares repurchased pursuant to the above Board of Directors’ resolution (as of April 22, 2026) *1

- | | |
|---|-------------------|
| (1) Total number of shares repurchased: | 1,000,000 shares |
| (2) Total amount of shares repurchased: | 1,344,434,100 yen |

*1 Based on the date of delivery

*2 Based on the date of contract

End